Nitazoxanide (NTZ)-37

Nitazoxanide (NTZ) is a synthetic broad-spectrum antiparasitic and antibacterial agent that was initially developed for the treatment of intestinal parasitic infections. Over time, its mechanism of action—targeting key metabolic pathways in pathogens—has been extensively studied, leading to its adoption in research settings for detecting and analyzing parasitic, protozoal, and bacterial interactions.
The Nitazoxanide (NTZ)-37 monoclonal antibody is specifically engineered to recognize and bind to NTZ, enabling precise detection and quantification of the compound in biological samples such as hair and saliva. This antibody is a critical tool for research studies focused on pharmacokinetics, exposure assessment, and the biological behavior of NTZ in various organisms.
Research applications of NTZ-related antibodies span multiple fields, including parasitology, microbiology, and pharmaceutical development. They support studies on drug efficacy, resistance mechanisms, and environmental exposure to NTZ, providing reliable data for advancing scientific understanding and potential therapeutic innovations.
With a threshold of 100 ng/mL for hair and saliva samples, this antibody is optimized to meet the sensitivity requirements of common research detection methods, ensuring accurate and reproducible results in laboratory settings.